Mr. Blum joined Gamida Cell’s board of directors as Chairman in September 2018, bringing more than 35 years of experience in the biopharmaceutical industry. Mr. Blum helped launch Cytokinetics in 1998 and served in roles of increasing responsibility before being appointed president and chief executive officer in 2007. Prior to launching Cytokinetics, Mr. Blum held senior positions in business development and marketing at COR Therapeutics and roles in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Additionally, Mr. Blum has served on the National Board of the American Committee of the Weizmann Institute of Science and he established the Blum Family Venture Philanthropy Fund to help advance basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy.
Mr. Blum holds bachelor’s degrees in Human Biology and Economics from Stanford University and an MBA from Harvard Business School.
Dr. Adams has more than 30 years of experience in drug discovery and development with a strong focus on cancer research. Dr. Adams joined Gamida Cell’s board of directors in 2016. Prior to being appointed CEO in November 2017, Dr. Adams served as chief scientific officer and president of Clal Biotechnology Industries. He was previously president of research and development at Infinity Pharmaceuticals. Prior to joining Infinity in 2003, Dr. Adams was the senior vice president of drug discovery and development at Millennium Pharmaceuticals, where he headed multiple global drug discovery and development programs, including the successful Velcade® (bortezomib) program. Dr. Adams also held senior positions in research and development at LeukoSite (acquired by Millennium) and at ProScript, as well as in medicinal chemistry at Boehringer Ingelheim, where he is credited with discovering Viramune® (nevirapine) for HIV. Dr. Adams has won several awards for his drug development efforts throughout his career, holds more than 40 patents from the United States Patent and Trademark Office (USPTO) and has authored more than 100 papers and book chapters in peer-reviewed journals. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology. He also earned a Doctor of Science, honoris causa, from McGill University in 2012.
Professor Roger Kornberg has been a Professor of Structural Biology at Stanford Medical School since 1978. He won the Nobel Prize for Chemistry in 2006 for his studies of the molecular basis of transcription, the process whereby information in DNA is read out for the direction of all activities of all organisms, including humans. Professor Kornberg began his career as a postdoctoral research fellow at the Laboratory of Molecular Biology in Cambridge, England and went on to be an Assistant Professor of Biological Chemistry at Harvard Medical School in 1976, before moving to his present position. Professor Kornberg is also the recipient of the 2006 Dickson Prize from University of Pittsburgh and the 2006 Louisa Gross Horwitz Prize from Columbia University. In 2009, he was elected a Foreign Member of the Royal Society. Professor Kornberg earned his bachelor’s degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972 supervised by Harden M. McConnell.
Dr. Michael Perry recently retired from Novartis, following a highly successful tenure where he served as SVP and Chief Scientific Officer, Global BD&L, Chief Scientific Officer, Cell & Gene Therapy Unit, Global Head, Cellular Therapy/VP, Integrated Hospital Care Franchise and as Novartis’ observer on the Gamida Cell Board of Directors. Novartis is a major shareholder in Gamida Cell. He is currently a Director and Operating Partner at venture capital firm Bioscience Managers Pty Ltd. Dr. Perry currently serves on the Boards of Avita Medical Ltd (AVH:ASX), Arrowhead Pharmaceuticals (ARWR:NASDAQ) and AmpliPhi Biosciences (APBH:NYSE). He is an Adjunct Professor at the University of Colorado, School of Medicine, Gates Center for Regenerative Medicine and Stem Cell Biology and serves as Chair of the Translational Medicine Advisory Board of the Houston Methodist Research Institute. Dr. Perry holds a Hon. B.Sc., in Physics from the University of Guelph in Ontario, Canada. He also earned a Doctorate in Veterinary Medicine & Surgery from the Ontario Veterinary College and a Ph.D. in Biomedical Science/Pharmacology from the University of Guelph.
Mr. Gonen has been with CBI since 2003. He manages the company’s life sciences investments, business development, US-based operations, and investment support for CBI’s portfolio companies. Mr. Gonen serves as an executive chairman and board member of several companies (Gamida Cell, MediWound (NASDAQ: MDWD), CureTech, D-Pharm (TASE: DPRM), Biocancell (TASE: BICL), Avraham, Campus Bio, Polyheal, CLS).
Prior to joining CBI, Mr. Gonen was the general manager of Biomedical Investments as well as a technology consultant to various Israeli venture capital funds and an Academic Aide to the Governor of the Bank of Israel. Mr. Gonen gained extensive experience in R&D and management in defense-oriented projects within the prestigious “TALPIOT” program of the Israeli Defence Forces, for which he was awarded the Israeli National Security Medal.
Mr. Gonen holds an M.A. in Economics and Finance from the Tel Aviv University, and a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University in Jerusalem.
Mr. Moch has more than 30 years of experience in building private and public life science companies. He currently serves as the President and CEO of Cognition Therapeutics, Inc., an Alzheimer’s disease therapeutics company, having previously served as a Managing Partner of The Salutramed Group, where he provided strategic and tactical counsel to biotechnology and medical products companies. He spent most of his career building and leading pioneering life science companies, and has served as the president and CEO of Chimerix Inc. (antiviral therapeutics), Biomedical Enterprises (orthopedic implants), Alteon Inc. (therapeutics for cardiovascular aging and diabetic complications), and Biocyte Corporation, where he pioneered the use of cord blood stem cells in transplantation therapy and launched the world’s first cord blood stem cell bank.
Earlier in his career Mr. Moch co-founded and served as the vice president of The Liposome Company, Inc. and served as a management consultant with McKinsey & Company. Mr. Moch currently sits on the Boards of Zynerba, Inc., M2Gen, the personalized medicine subsidiary of the Moffitt Cancer Center, and the Biotechnology Innovation Association (BIO). He is also a member of the New York University Working Group of Compassionate Use and Pre-Approval Access. Mr. Moch holds an A.B. in biochemistry from Princeton University and an M.B.A. from the Stanford University Graduate School of Business.
Boaz Lifschitz is a General Partner and Co- Founder of Peregrine Ventures. Boaz serves on behalf of Peregrine Ventures on the Boards of Cartiheal Ltd., WhiteSource as a Board observer in Rocketick Ltd. and other companies.
Boaz serves as a director in Elbit Imaging Ltd. (EMITF), in Insightec Ltd. Boaz also served as a Director of Neovasc Inc (NVCN) in 2009-2011. Prior to co-founding Peregrine Ventures, Boaz was a Co-founder of Visioncare Ltd. and BioControl Ltd. both biomedical device companies. Boaz also acquired vast experience in financing technology based companies, having been responsible for reviewing potential investments in early and mid-stage stage companies.
Mr. Lifschitz holds a B.Sc. from Bar-Ilan University as well as a M.Sc. from Boston University jointly with Ben Gurion University.